Clearside Biomedical announces medical meeting presentations on pipeline

Clearside Biomedical (CLSD) announced recent and upcoming presentations at ophthalmic medical meetings highlighting Clearside’s suprachoroidal delivery technology and promising pipeline, including its Phase 3 ready CLS-AX program for the treatment of neovascular age-related macular degeneration. “Our medical meetings this quarter continue to demonstrate the commercial, clinical and regulatory expertise that establishes Clearside as the leader in suprachoroidal delivery,” said Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development. “We are excited about the potential of our CLS-AX program and look forward to presenting additional data from our Phase 2b ODYSSEY trial at upcoming meetings.”